tbuckley/cabot-search huggingface dataset:
"STANDARDS OF OPHTHALMOLOGY"
Authors: George S. Derby
Journal: JAMA (1924)

<h3>To the Editor:</h3> —Mr. Coe (The Journal, September 27, p. 1021) is quite right in thinking that my statement as to the profit on glasses might be misleading to the general public. As a matter of fact, my address was delivered to members of the medical profession and with no thought of the general public. According to my information, glasses are sold by the first class opticians at an advance of about 100 per cent. over the price they pay the manufacturer. This is by no means all profit, as the time spent in fitting and readjusting must be taken into account, as well as the large overhead charge which is carried by those firms which aspire to the high class trade. This is not true, to the same degree, of the oculist who sells his own glasses. His overhead charge is not nearly so great and his profit is
Analysis of prognostic factors in superficial urinary bladder carcinoma in our set up-a study in Jammu, J&K, India
Authors: S. Sharma, A. K. Gupta, L. Gupta, J. Suri
Journal: Journal of Clinical Oncology (2004)

4713 Objective: Urinary bladder carcinoma is one of the most common malignancies. The disease incidence is on a constant rise in our area because of the better patient awareness, awareness amongst the physicians and the timely referral of the patients to the institutes where these are treated. We have analyzed the various prognostic factors that could be used to predict the outcome of the management of the superficial bladder carcinoma. Patients and Methods: 123 patients who underwent transurethral resection for superficial bladder tumors were evaluated for the analysis of the prognostic factors like tumor type, size, stage, grade multicentricity, architecture of the infiltration (papillary or solid), recurrence in first three months and associated CIS were the parameters taken for the consideration. Results: 76% patients had papillary type of the tumor and 24% had nodular type. Most of the patients with the papillary type had superficial recurrence and the nodular type had the invasive one. Tumors confined to the mucosa had recurrence in 3% of the cases.27% with the lamina propria involvement progressed to the invasive disease. Low-grade papillary tumors confined to the mucosa appear to have a low risk of recurrence and almost no risk of progression. Stage T1 tumors had high grade and increased risk of progression. Tumors with <1 cm, 1–2 cm and 2–5 cm had a recurrence rate of 22.2%, 29.4% and 31.2%26% of the patients had grade1 disease, 34% grade 11 and 40% grade 111 .43% of the patients showed recurrence during the first three months follow up check cystoscopy. Conclusion: Superficial urinary bladder carcinoma treated largely depends upon the multiple factors. Tumors with papillary type, low stage, low grade, no recurrence in the first three months, small size tumors and favorable differentiation pathologically are responsible for the excellent outcome with less chances of the progression of the disease. No significant financial relationships to disclose.
Accountability, audit, and reverence for the publication process
Authors: D. Rennie
Journal: JAMA (1993)

Let me begin with a few truisms, just to be sure that we are operating on a common ground of reverence for the publication process —Above all, the act of publication is an inscription under oath, a testimony. It is accepted as valid until firm evidence to the contrary is presented. There is an extremely high level of accountability for what is published under a given person's name.... It is the essential ingredient to make scientific work responsible in the sense that one cannot readily retreat from assertions that have been signed, delivered to the printer, and made available to thousands!—Joshua Lederberg<sup>1</sup> Having long subscribed to the approach that each author carries a heavy responsibility for what appears under his or her name, I had been impressed when several articles I had accepted for publication were later found by Food and Drug Administration (FDA) audit to be based on
Gene Therapy
Authors: W. French Anderson
Journal: JAMA (1981)

<h3>Can Gene Therapy Help Me?</h3> This article is designed to help the practicing physician answer the patient with a genetic disease who asks, "Can gene therapy help me?" The answer depends on the patient's disease, but for some genetic conditions, gene therapy should be a beneficial therapeutic procedure in the coming years. This brief review examines the present state of the art, points out what still needs to be accomplished before gene therapy will be practical, and concludes by suggesting the potential and the limitations of this promising, but not yet available, technology. Progress in the area of "genetic engineering" has been spectular in recent years. Not only are bacteria being programmed to produce medically useful compounds (insulin, growth hormone, etc), but genes have been transferred into mammalian cells successfully. Individual cells in tissue culture have been cured of genetic defects by insertion of a normal gene.<sup>1-3</sup>Purified genes
El Niño and arboviral disease prediction.
Authors: D Maelzer, S Hales, P Weinstein, M Zalucki, A Woodward
Journal: Environmental Health Perspectives (1999)

Recent El Niño events have stimulated interest in the development of modeling techniques to forecast extremes of climate and related health events. Previous studies have documented associations between specific climate variables (particularly temperature and rainfall) and outbreaks of arboviral disease. In some countries, such diseases are sensitive to El Niño. Here we describe a climate-based model for the prediction of Ross River virus epidemics in Australia. From a literature search and data on case notifications, we determined in which years there were epidemics of Ross River virus in southern Australia between 1928 and 1998. Predictor variables were monthly Southern Oscillation index values for the year of an epidemic or lagged by 1 year. We found that in southeastern states, epidemic years were well predicted by monthly Southern Oscillation index values in January and September in the previous year. The model forecasts that there is a high probability of epidemic Ross River virus in the southern states of Australia in 1999. We conclude that epidemics of arboviral disease can, at least in principle, be predicted on the basis of climate relationships.
Public Relief of Sickness.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells
Authors: Pleun Hombrink, Christina Helbig, Ronald A Backer, Berber Piet, Anna E Oja, Regina Stark, Giso Brasser, Aldo Jongejan, René E Jonkers, Benjamin Nota, Onur Basak, Hans C Clevers, Perry D Moerland, Derk Amsen, René A W van Lier
Journal: Nature Immunology (2017)
DILATATION OF STOMACH DUE TO COMPRESSION OF DUODENO-JEJUNAL JUNCTION BY MESENTERIC ARTERY AND ROOT OF MESENTERY.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease
Authors: Feng Hong, Svetlana Radaeva, Hong-Na Pan, Zhigang Tian, Richard Veech, Bin Gao
Journal: Hepatology (2004)

Fatty liver, formerly associated predominantly with excessive alcohol intake, is now also recognized as a complication of obesity and an important precursor state to more severe forms of liver pathology including ischemia/reperfusion injury. No standard protocol for treating fatty liver exists at this time. We therefore examined the effects of 10 days of interleukin 6 (IL-6) injection in 3 murine models of fatty liver: leptin deficient ob/ob mice, ethanol-fed mice, and mice fed a high-fat diet. In all 3 models, IL-6 injection decreased steatosis and normalized serum aminotransferase. The beneficial effects of IL-6 treatment in vivo resulted in part from an increase in mitochondrial β oxidation of fatty acid and an increase in hepatic export of triglyceride and cholesterol. However, administration of IL-6 to isolated cultured steatotic hepatocytes failed to decrease lipid contents, suggesting that the beneficial effects of IL-6 in vivo do not result from its effects on hepatocytes alone. IL-6 treatment increased hepatic peroxisome proliferator-activated receptor (PPAR) α and decreased liver and serum tumor necrosis factor (TNF) α. Finally, 10 days of treatment with IL-6 prevented the susceptibility of fatty livers to warm ischemia/reperfusion injury. In conclusion, long-term IL-6 administration ameliorates fatty livers and protects against warm ischemia/reperfusion fatty liver injury, suggesting the therapeutic potential of IL-6 in treating human fatty liver disease. Supplementary material for this article can be found on the Hepatology website (http://interscience.wiley.com/jpages/0270-9139/suppmat/index.html). (HEPATOLOGY 2004;40:933–941.)
Handbook of Physiology.
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ON THE COVERShould Doctors Ever Lie on Behalf of Patients?Physicians' Duties in an Era of Cost Containment: Advocacy or Betrayal?Community Considerations: The Many Effects of MiscodingServing Two Masters: Medical Practice vs Administrative Ethics2000 John Conley Ethics Essay Contest for Medical Students
Journal: JAMA (1999)

A PATIENT'S DIAGNOSIS falsely ina medical record to gain benefits for the patient?The small amount of empirical research available suggests that many physicians do indeed choose to deceive third-party payers.In a decade-old survey, 70% of a sample of clinicians stated that hypothetically, they would write "rule out cancer" to secure funding for screening mammography if the patient's insurance would not otherwise fund it. 1 Nearly half the physicians in a more recent survey admitted to exaggerating the severity of patients' conditions to get the care they felt the patient needed. 2 In another study, in 1998, 39% of the physician sample admitted to exaggerating the severity of patients' conditions, changing official billing diagnoses, and documenting nonexistent symptoms-all to gain additional benefits for patients. 3 Several approaches to such a dilemma have been articulated.One consider the ethics of lying.Sissela Bok champions the "principle of veracity," which emphasizes the intrinsic moral undesirability of a lie because no one likes to be deceived. 4 Others worry about the effect lying would have on trust on the patient-physician relationship. 5 Still others worry that exaggerated and inaccurate diagnoses may frighten patients and compromise their future clinical care. 6 Alternatively, the question may be interpreted as one of distributive justice.The reimbursement boundaries set by third-party payers are a de facto resource allocation mechanism.Much has been written about whether physicians should ever withhold available interventions because of a high cost-to-benefit ratio. 7,8 The same reasoning applies to the question of whether physicians should ever transgress reimbursement boundaries to secure benefits not covered by insurance plans.Entrants in the 1999 John Conley Ethics Essay Contest for Medical Students were asked: "Suppose a potentially useful procedure is available that is not covered by a patient's medical insurance.Under what circumstances, if any, would you consider it appropriate to miscode (and thereby make available) the needed procedure?"Peter Ubel, MD, frames the issue as a question of distributive justice.Then, from opposed perspectives, the winners of this year's contest argue that miscoding is unethical because of its effect on the "medical commons" (Dena Rifkin) and that miscoding is sometimes justifiable based on the role society accords physicians (Greg Webster).On reading these essays, we hope readers will be better equipped to answer this question for themselves.
PROFESSIONAL SECRECY AND CRIMINALS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SANITARY RECOMMENDATIONS OF THE SURGEONGENERAL OF THE ARMY.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Schizophrenia therapy controversy continues
Authors: P. Cotton
Journal: JAMA (1991)

ENDING an exclusivity arrangement may not ease the threat of antitrust actions against the Sandoz Pharmaceutical Co of East Hanover, NJ. The Antitrust Subcommittee of the US Senate Judiciary Committee heard testimony this month concerning the company's continued insistence on controlling physician monitoring of patients taking its schizophrenia drug clozapine (Clozaril) because of concerns about product liability suits. Sandoz sent no representative to the hearing, citing a conflict with ongoing antitrust suits brought by attorneys general of 29 states and the District of Columbia (<i>JAMA</i>. 1991;265:837-838). David Winter, MD, vice president for scientific and external affairs, says there is "no basis for antitrust" now, or even with the original exclusive linkage arrangement, under which patients could only get the drug by submitting to weekly monitoring by Caremark Home-care Inc of Lincolnshire, Ill. The testing is for agranulocytosis, a blood disorder affecting 1% to 2% of patients that can be fatal
The creatinine approach to estimate skeletal muscle mass in patients with cirrhosis
Authors: M Pirlich
Journal: Hepatology (1996)

The creatinine-method to estimate muscle mass is frequently used in clinical studies, although the validity of this approach is uncertain in patients with cirrhosis. In this study 102 patients with cirrhosis differing in cause, clinical state, liver, and renal function were investigated to determine whether reduced liver or renal function may explain in part the low levels of urinary creatinine excretion frequently observed in these patients. Muscle mass assessed by 24-hour urinary creatinine excretion was compared with anthropometrically obtained muscle mass calculated from arm muscle area (AMA), and with body cell mass (BCM) estimated by bioelectrical impedance analysis and total body potassium counting. In cirrhosis, the 24-hour urinary creatinine excretion was 10.4% and AMA was 19% lower than predicted values. The differences between the results obtained by different methods did not show any relation to parameters of liver function (ICG- t½, caffeine-t½, MEGX-test, cholinesterase) or the severity of liver disease (i.e., Child-Pugh score). In contrast, renal function was strongly correlated with the differences between creatinine- and anthropometric-muscle mass (r = .64, P < .001). At the same time, patients with normal renal function (62% of the whole population) had significantly higher creatinine (29.1 ± 8.5 vs. 15.8 ± 6 kg, P < .001) and anthropometric-muscle mass (22.4 ± 6 vs. 17.9 ± 5.3 kg; P < .01) than patients with reduced renal function (38% of the patients). In addition, significantly higher differences between measured and predicted values of urinary creatinine excretion (-0.389 ± 0.33 vs. 0.06 ± 0.31 g/24 h; P < .001) and of AMA (13.2 ± 12 vs. 7.2 ± 12 cm2; P < .03) were found in the subgroup with impaired renal function. In conclusion, renal dysfunction but not reduced liver function systematically affects the urinary creatinine method for the estimation of skeletal muscle mass in cirrhosis.
Second Report of the Wellcome Research Laboratories at the Gordon Memorial College. Khartoum. Africa.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AMAgrams
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal